Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study
Open accessThe DOI matches its Crossref record.
Abstract
OBJECTIVE: To measure the efficacy of sulfadoxine-pyrimethamine treatment of falciparum malaria in Malawi from 1998 to 2002, after a change from chloroquine to sulfadoxine-pyrimethamine as first line treatment in that country in 1993. DESIGN: Prospective open label drug efficacy study. SETTING: Health centre in large peri-urban township adjacent to Blantyre, Malawi. PARTICIPANTS: People presenting to a health centre with uncomplicated Plasmodium falciparum malaria. MAIN OUTCOME MEASURES: Therapeutic efficacy and parasitological resistance to standard sulfadoxine-pyrimethamine treatment at 14 days and 28 days of follow up. RESULTS: Therapeutic efficacy remained stable, with adequate clinical response rates of 80% or higher throughout the five years of the study. Analysis of follow up to 28 days showed modest but significant trends towards diminishing clinical and parasitological efficacy over time within the study period. CONCLUSION: Contrary to expectations, sulfadoxine-pyrimethamine has retained good efficacy after 10 years as the first line antimalarial drug in Malawi. African countries with very low chloroquine efficacy, high sulfadoxine-pyrimethamine efficacy, and no other immediately available alternatives may benefit from interim use of sulfadoxine-pyrimethamine while awaiting implementation of combination antimalarial treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mechanisms of Resistance of Malaria Parasites to Antifolates
Gregson, A., & Plowe, C. V. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.1.4 · Cited by 499
Self-citationGreenwood, B. M., Bojang, K., Whitty, C. J., & Targett, G. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66420-3 · Cited by 497
Return of Chloroquine Antimalarial Efficacy in Malawi
Laufer, M. K., Thesing, P. C., Eddington, N. D., Masonga, R., Dzinjalamala, F. K., Takala, S. L., Taylor, T. E., & Plowe, C. V. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062032 · Cited by 432
Self-citationO. ter Kuile, F., van Eijk, A. M., & Filler, S. J. (2007) · JAMA · doi:10.1001/jama.297.23.2603 · Cited by 355
WHO Guidelines for the treatment of malaria
Kunte, R., & Kunwar, R. (2011) · Medical Journal Armed Forces India · doi:10.1016/s0377-1237(16)30022-3 · Cited by 341
Intermittent Presumptive Treatment for Malaria
White, N. J. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020003 · Cited by 269
Peters, P. J., Thigpen, M. C., Parise, M. E., & Newman, R. D. (2007) · Drug Safety · doi:10.2165/00002018-200730060-00003 · Cited by 174
Filler, S. J., Kazembe, P., Thigpen, M., Macheso, A., Parise, M. E., Newman, R. D., Steketee, R. W., & Hamel, M. (2006) · The Journal of Infectious Diseases · doi:10.1086/505080 · Cited by 108
“During this period, there have been significant trends toward diminishing clinical and parasitological efficacy of SP for the treatment of children with uncomplicated malaria [23].”
Kalilani, L., Mofolo, I., Chaponda, M., Rogerson, S. J., Alker, A. P., Kwiek, J. J., & Meshnick, S. R. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001166 · Cited by 75
“The prevalence of clinical failure and drug resistance mutations in parasite enzymes associated with resistance to SP have risen in recent years [34,47], but currently SP is still effective as IPT [48].”
Feng, G., Aitken, E., Yosaatmadja, F., Kalilani, L., Meshnick, S. R., Jaworowski, A., Simpson, J. A., & Rogerson, S. J. (2009) · The Journal of Infectious Diseases · doi:10.1086/599841 · Cited by 69
“Prevention of malaria in pregnancy in Africa still relies on sulfadoxine-pyrimethamine (SP), but parasite resistance leads to treatment failures in children [22].”
Wilson, N. O., Ceesay, F. K., Obed, S. A., Adjei, A. A., Gyasi, R. K., Rodney, P., Ndjakani, Y., Anderson, W. A., Lucchi, N. W., & Stiles, J. K. (2011) · The American Society of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2011.10-0512 · Cited by 58
Metadata
- Authors
- Plowe, C. V., Kublin, J. G., Dzinjalamala, F. K., Kamwendo, D. S., Chimpeni, P., Molyneux, M. E., & Taylor, T. E.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2004-02-02
- Volume
- 328
- Issue
- 7439
- Pages
- 545
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2037241522
- Cited by
- 93
- References
- 0
- FWCI
- 15.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.